CervoMed Inc.

Stage 4 · Declining · week 37

As of Oct 22, 2026, CervoMed is in Stage 4, the downtrend phase, now in week 37 (since Jan 29, 2026). It closed at $2.24, 77.5% below its 52-week high and below its 200-day average, which is falling.

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. More about the company

$2.24

-2.84% today

$33.9M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is CRVO early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 17w

S4 28w

S4 38w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 2w → S1 9w → S2 10w → S3 5w → S2 17w → S3 11w → S4 28w → S1 9w → S2 4w → S3 8w → S2 9w → S3 7w → S4 1w → S1 7w → S4 38w current

Total tracked: 165 weeks across 15 stage runs.

CRVO among Biotechnology417th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…417	CRVOCervoMed Inc.	Stage 4 · wk 37	16	−10.8%

vs 52W High

-77.5%

$2.24 lo$9.94 hi

77.5% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 37

1w13w26w

Week 37, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-39.1%

200 DMA: $3.68 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.37x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-10.8%

-15.8%

-41.8%

YTD

-71.2%

-69.0%

Scan Membership

Breakout Watch

Latest: 2025-05-20

6 appearances in last 60 days. First seen: 2019-04-17.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 37 · Vol 0.37x

2026-10-21S4

Wk 37 · Vol 0.28x

2026-10-20S4

Wk 37 · Vol 0.48x

2026-10-19S4

Wk 37 · Vol 0.74x

2026-10-16S4

Wk 37 · Vol 0.34x

2026-10-15S4

Wk 36 · Vol 0.69x

2026-10-14S4

Wk 36 · Vol 1.67x

2026-10-13S4

Wk 36 · Vol 1.87x

2026-10-12S4

Wk 36 · Vol 3.24x

2026-10-09S4

Wk 36 · Vol 0.85x

2026-10-08S4

Wk 35 · Vol 1.24x

2026-10-07S4

Wk 35 · Vol 1.12x

Moving averages & range

50 DMA

$2.63

200 DMA

$3.68

52W High

$9.94

52W Low

$2.24

5D Low

$2.24

Resistance levels (recent highs)

20d High

$3.34

60d High

$3.34

120d High

$4.52

250d High

$9.94

Next resistance

+49.1%

to 20d High

ROE

-107.6%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 1.3

CervoMed: quick answers

What stage is CervoMed in?

As of Oct 22, 2026, CervoMed (CRVO) is in Stage 4, the downtrend phase. It entered Stage 4 on Jan 29, 2026 and is in week 37. What the four stages mean

Is CervoMed in an uptrend?

No. CervoMed is in a Stage 4 downtrend. It trades 39.1% below its 200-day average, which is falling.

How far is CervoMed from its 52-week high?

CervoMed closed at $2.24 on Oct 22, 2026, 77.5% below its 52-week high of $9.94. Its 52-week low is $2.24.

How has CervoMed performed over the past year?

As of Oct 22, 2026, CervoMed is down 69.0% over the past year and down 71.2% so far in 2026.

Which sector and industry is CervoMed in?

CervoMed is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.